<DOC>
	<DOCNO>NCT01329640</DOCNO>
	<brief_summary>The purpose study evaluate safety , effectiveness cost-effectiveness metronomic chemotherapy combine trastuzumab neoadjuvant therapy locally advance HER2-positive breast cancer .</brief_summary>
	<brief_title>Feasibility Study Metronomic Chemotherapy Locally Advanced Her2- Positive Breast Cancer ( TraQ-Me 01 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Diagnosis locally advance breast cancer T &gt; 2 cm ( N ) , T positive node ( needle biopsy require tumor size le 2cm ) Nonmetastatic disease confirm computerized tomography bone scan HER2 positive IHC ( +++ ) and/or Fish ( + ) accord international definition ( ASCO 2007 ) Normal leave ventricular ejection fraction ( LVEF ) Indication preoperative chemotherapy multifocal tumor acceptable provide large tumor Her2positive ECOG 01 Another malignancy within last 5 year ( except curatively treat skin carcinoma , situ cervix carcinoma , situ ductal carcinoma breast , situ lobular carcinoma breast ) Clinically significant comorbidities cardiovascular disease , COPD , renal liver impairment , psychiatric disorder LVEF value institutional limit normal range Detected suspect distant metastasis Neutrophils low 1,500/µL , platelet low 100,000/µL , hemoglobin low 10 g/dL , AST high 2.5x upper limit normal ( ULN ) , total bilirubin high ULN , alkaline phosphatase 1.5x ULN</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Metronimic chemotherapy</keyword>
	<keyword>Locally Advanced HER2-positive Breast Cancer</keyword>
</DOC>